Advertisement

Lasers in Medical Science

, Volume 33, Issue 3, pp 589–595 | Cite as

Benign prostatic hyperplasia surgical scoring (BPHSS): an novel scoring system for the perioperative outcomes of holmium laser enucleation of the prostate

  • Huan Xu
  • Zhikang Cai
  • Yanbo Chen
  • Meng Gu
  • Qi Chen
  • Zhong Wang
Original Article
  • 136 Downloads

Abstract

To develop a standardized scoring system, the BPH surgical scoring (BPHSS) system, to quantify the ability to predict the perioperative outcomes resulting from an enlarged prostate. There are two parts included in this study: the retrospective observational study (875 patients treated with holmium laser enucleation of the prostate, HoLEP) and the prospective observational study (111 patient underwent HoLEP). All the outcome data included the following: the basic patient preoperative characteristics, operation time (OT), pre- and post- surgery hemoglobin decrease, Na+ variation, hospital stay duration, duration of bladder irrigation, catheterization time, and hospitalization time. The BPHSS, consisting of prostatic volume (PV), prostate-specific antigen (PSA), bladder stones, intravesical prostatic protrusion (IPP), and metabolic syndrome (MetS), was observed regarding the perioperative outcomes. In the retrospective study, patients in high BPHSS group (6–8 points) showed significant increase in the OT (74.61, 95%CI = 16.98–327.84, P < 0.001), hemochrome reduction (416.50, 95%CI = 35.48–4889.88, P < 0.001), hospital stay (1.80, 95%CI = 1.35–2.41, P < 0.001), and bladder irrigation duration (4.04, 95%CI = 1.35–12.10, P = 0.013) compared with the low BPHSS group (0–2 points). In the prospective study, there also existed significant differences between the three scoring grades (P < 0.01) in OT, hemochrome decrease, and the hospital stay. The BPHSS is suitable to predict the perioperative outcomes in patients undergoing HoLEP. It may help urologist to prepare more before surgery to treat the enlarged prostates. Further studies are needed to validate this scoring system in BPH patients in multiple centers.

Keywords

Benign prostatic hyperplasia Holmium laser enucleation of the prostate Perioperative outcomes Scoring system 

Abbreviations

BPH

benign prostatic hyperplasia

BPHSS

BPH surgical scoring

HoLEP

holmium laser enucleation of the prostate

OT

operation time

PV

prostatic volume

PSA

prostate-specific antigen

IPP

intravesical prostatic protrusion

MetS

metabolic syndrome

TUEP

transurethral enucleation of the prostate

TURP

transurethral resection of the prostate

PVR

postvoid residual

ROC

receiver operating characteristic

EAU

European Association of Urology

AUC

area under the curve

OAB

overactive bladder

PAE

prostatic arterial embolization

5ARI

5-α reductase inhibitors

LUTS

lower urinary tract symptoms

Notes

Funding information

This research was supported by Shanghai Pudong new area health and family planning project (NO. PW2013D-3), key disciplines group construction project of Pudong Health Bureau of Shanghai (PWZxq2014-11), Program for Outstanding Medical Academic Leader, and Speciality Construction Project of Pudong Health, and Family Commission of Shanghai (NO. PWZz2013-16).

Compliance with ethical standards

Conflict of interest

The authors declare that they have no competing interests.

Ethical approval

Ethics approval and consent to participate: ethical approval of the patients were obtained in our study from Shanghai 9th People’s Hospital Ethics Committee.

Informed consent

Written informed consent was obtained from each patient.

Supplementary material

10103_2017_2425_Fig2_ESM.gif (181 kb)
Supplemental Figure 1

The flow diagram of this trial. (GIF 180 kb)

10103_2017_2425_MOESM1_ESM.tif (2.6 mb)
High resolution image (TIFF 2709 kb)
10103_2017_2425_MOESM2_ESM.docx (17 kb)
Supplemental Table 1 (DOCX 16 kb)

References

  1. 1.
    Oelke M et al (2013) EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol 64(1):118–140CrossRefPubMedGoogle Scholar
  2. 2.
    Kahokehr A, Gilling PJ (2014) Enucleation techniques for benign prostate obstruction: which one and why? Curr Opin Urol 24(1):49–55CrossRefPubMedGoogle Scholar
  3. 3.
    Rieken M, Bachmann A (2014) Laser treatment of benign prostate enlargement--which laser for which prostate? Nat Rev Urol 11(3):142–152CrossRefPubMedGoogle Scholar
  4. 4.
    Zhang X et al (2016) Different lasers in the treatment of benign prostatic hyperplasia: a network meta-analysis. Sci Rep 6:23503CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Grundy SM et al (2005) Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112(17):2735–2752CrossRefPubMedGoogle Scholar
  6. 6.
    Chen YB et al (2013) A prospective, randomized clinical trial comparing plasmakinetic resection of the prostate with holmium laser enucleation of the prostate based on a 2-year followup. J Urol 189(1):217–222CrossRefPubMedGoogle Scholar
  7. 7.
    van Rij S, Gilling PJ (2012) In 2013, holmium laser enucleation of the prostate (HoLEP) may be the new 'gold standard'. Curr Urol Rep 13(6):427–432CrossRefPubMedGoogle Scholar
  8. 8.
    Tan AH, Gilling PJ (2003) Holmium laser prostatectomy. BJU Int 92(6):527–530CrossRefPubMedGoogle Scholar
  9. 9.
    Geavlete B et al (2013) Bipolar plasma enucleation of the prostate vs open prostatectomy in large benign prostatic hyperplasia cases—a medium term, prospective, randomized comparison. BJU Int 111(5):793–803CrossRefPubMedGoogle Scholar
  10. 10.
    Elzayat EA, Habib EI, Elhilali MM (2005) Holmium laser enucleation of the prostate: a size-independent new “gold standard”. Urology 66(5 Suppl):108–113CrossRefPubMedGoogle Scholar
  11. 11.
    Busetto GM et al (2015) Short-term pretreatment with a dual 5α-reductase inhibitor before bipolar transurethral resection of the prostate (B-TURP): evaluation of prostate vascularity and decreased surgical blood loss in large prostates. BJU Int 116(1):117–123CrossRefPubMedGoogle Scholar
  12. 12.
    Netsch C et al (2012) Thulium:YAG vapoEnucleation of the prostate in large glands: a prospective comparison using 70- and 120-W 2-microm lasers. Asian J Androl 14(2):325–329CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Lee DJ et al (2016) Laser vaporization of the prostate with the 180-W XPS-greenlight laser in patients with ongoing platelet aggregation inhibition and oral anticoagulation. Urology 91:167–173CrossRefPubMedGoogle Scholar
  14. 14.
    Gilling P, Anderson P, Tan A (2017) Aquablation of the prostate for symptomatic benign prostatic hyperplasia: 1-year results. J Urol 197(6):1565–1572Google Scholar
  15. 15.
    Keehn A et al (2017) UroLift in place of fiducial markers for patients with benign prostatic hyperplasia undergoing external beam radiation therapy. Urology 104:230–234CrossRefPubMedGoogle Scholar
  16. 16.
    Jeong CW et al (2010) Minimally invasive management of postoperative bleeding after radical prostatectomy: transarterial embolization. J Endourol 24(9):1529–1533CrossRefPubMedGoogle Scholar
  17. 17.
    Kuntz RM, Lehrich K, Ahyai SA (2008) Holmium laser enucleation of the prostate versus open prostatectomy for prostates greater than 100 grams: 5-year follow-up results of a randomised clinical trial. Eur Urol 53(1):160–166CrossRefPubMedGoogle Scholar
  18. 18.
    Monn MF et al (2015) Predictors of enucleation and morcellation time during holmium laser enucleation of the prostate. Urology 86(2):338–342CrossRefPubMedGoogle Scholar
  19. 19.
    Hirayama K et al (2015) Evaluation of intravesical prostatic protrusion as a predictor of dutasteride-resistant lower urinary tract symptoms/benign prostatic enlargement with a high likelihood of surgical intervention. Urology 86(3):565–569CrossRefPubMedGoogle Scholar
  20. 20.
    Lee JY et al (2012) Single-port transvesical enucleation of the prostate for benign prostatic hyperplasia with severe intravesical prostatic protrusion. World J Urol 30(4):511–517CrossRefPubMedGoogle Scholar
  21. 21.
    Marks LS, Roehrborn CG, Andriole GL (2006) Prevention of benign prostatic hyperplasia disease. J Urol 176(4 Pt 1):1299–1306CrossRefPubMedGoogle Scholar
  22. 22.
    Roehrborn CG et al (2001) Clinical predictors of spontaneous acute urinary retention in men with LUTS and clinical BPH: a comprehensive analysis of the pooled placebo groups of several large clinical trials. Urology 58(2):210–216CrossRefPubMedGoogle Scholar
  23. 23.
    Roehrborn CG et al (1999) Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia. Urology 53(3):581–589CrossRefPubMedGoogle Scholar
  24. 24.
    Ma D et al (2014) Correlation between molecular biomarkers and risk factors for the clinical progression of benign prostatic hyperplasia using tissue microarray immunostaining. Chin Med J 127(23):4031–4035PubMedGoogle Scholar
  25. 25.
    Choo MS et al (2014) Transurethral surgical anatomy of the arterial bleeder in the enucleated capsular plane of enlarged prostates during holmium laser enucleation of the prostate. Int Neurourol J 18(3):138–144CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Roehrborn CG (2004) The clinical benefits of dutasteride treatment for LUTS and BPH. Rev Urol 6(Suppl 9):S22–S30PubMedPubMedCentralGoogle Scholar
  27. 27.
    Ozden C et al (2007) The correlation between metabolic syndrome and prostatic growth in patients with benign prostatic hyperplasia. Eur Urol 51(1):199–203 discussion 204-6CrossRefPubMedGoogle Scholar
  28. 28.
    Muller RL et al (2013) Obesity is associated with increased prostate growth and attenuated prostate volume reduction by dutasteride. Eur Urol 63(6):1115–1121CrossRefPubMedGoogle Scholar
  29. 29.
    De Nunzio C et al (2012) The correlation between metabolic syndrome and prostatic diseases. Eur Urol 61(3):560–570CrossRefPubMedGoogle Scholar
  30. 30.
    Vignozzi L, Gacci M, Maggi M (2016) Lower urinary tract symptoms, benign prostatic hyperplasia and metabolic syndrome. Nat Rev Urol 13(2):108–119CrossRefPubMedGoogle Scholar
  31. 31.
    Xu H et al (2017) Oxytocin: its role in benign prostatic hyperplasia via the ERK pathway. Clin Sci (Lond) 131(7):595–607Google Scholar
  32. 32.
    Kasturi S, Russell S, McVary KT (2006) Metabolic syndrome and lower urinary tract symptoms secondary to benign prostatic hyperplasia. Curr Urol Rep 7(4):288–292CrossRefPubMedGoogle Scholar
  33. 33.
    Miller DC, Park JM (2003) Percutaneous cystolithotomy using a laparoscopic entrapment sac. Urology 62(2):333–336 discussion 336CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag London Ltd., part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Urology, Shanghai Ninth People’s HospitalShanghai Jiao tong University School of MedicineShanghaiChina

Personalised recommendations